Drug Trial Radar · NCT00772928
Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™
Last checked: Nov 20, 2026Latest source record: Feb 1, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,167
Actual
Start
Oct 2003
Primary completion
May 2006
Study completion Nov 2006
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Oct 15, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 42 days, up to 89 days
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is designed to evaluate in a controlled manner the effect of Prevnar® on the immune responses of Pentacel™ Primary Objective - Stage I: To compare the immune responses elicited by an infant series of Pentacel™ when given at different times from or concurrently with a Pneumococcal conjugate vaccine (Prevnar®). Primary Objective - Stage II: To compare the immune responses elicited by a 4th dose of Pentacel™ when given at different times from or concurrently with Prevnar®.
Conditions
- Diphtheria
- Tetanus
- Haemophilus Infection
- Pertussis
- Polio
Interventions
Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®Biological
0.5 mL, Intramuscular
Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®Biological
0.5 mL, Intramuscular
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With 4-fold Rises in Levels of Pentacel™ Vaccine Antibody Titers Post-dose 3 When Given at Different Times or Concurrently With a Pneumococcal Conjugate Vaccine (Prevnar®)Time frame: 28 to 48 days post-3rd vaccination
- Geometric Mean Titers of Antibodies to Pertussis, Diphtheria, Tetanus, Polyribosylribitol Phosphate and Poliovirus Elicited by an Infant Series of Pentacel™ When Given at Different Times or Concurrently With a Pneumococcal Conjugate Vaccine (Prevnar®)Time frame: 60 Days Post-dose 3
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Montgomery, Alabama
Site not named
Fayetteville, Arkansas
Site not named
Jonesboro, Arkansas
Site not named
Little Rock, Arkansas
Site not named
Fountain Valley, California
Site not named
Oakland, California
Site not named
Rolling Hills Estate, California
Site not named
Norwich, Connecticut
Site not named
Bardstown, Kentucky
Site not named
Louisville, Kentucky
Site not named
Boston, Massachusetts
Site not named
Kansas City, Missouri
Site not named
Brooklyn, New York
Site not named
Norristown, Pennsylvania
Site not named
Pittsburgh, Pennsylvania
Site not named
Austin, Texas
Site not named
Fort Worth, Texas
Site not named
San Antonio, Texas
Site not named
San Antonio, Texas
Site not named
Layton, Utah
Site not named
Spokane, Washington
Site not named
Vancouver, Washington
Site not named
La Crosse, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.